Novo Nordisk’s Earnings Surge on Frenzy for Obesity Drugs

Novo Nordisk flags continued restrictions on Wegovy supplies

When Japan Ends Negative Rate Policy, Treasuries Will Suffer

China Weight-Loss Drug Stocks Lose Shine on ‘Misleading’ Claims

Novo Nordisk in $1.3 billion deal to buy hypertension drug

A $245 Billion Selloff Signals Less Sparkly Future for Luxury Stocks

Novo’s Blockbuster Ozempic Now Shows Kidney Promise, Hitting Rivals 

LVMH Sales Growth Slows as Global Luxury Demand Cools

Novo Nordisk's Wegovy bonanza looms large in Denmark

Ozempic Is Causing ‘Slight Pullback’ by Shoppers, Walmart Says

If Ozempic Makes People Eat Less, Maker of Cheez-It Will Be Ready

Weight-Loss Drugmaker Carmot Therapeutics Is Considering IPO